A groundbreaking work by Mater Research scientists is giving new hope by targeting molecules on a key immune system trigger known as dendritic cells.
Professor Kristen Radford from Mater Research told 9News that by focusing on that cell type in particular, they think they could develop a vaccine to help fight the disease and to eventually help prevent recurrence.
The vaccine development is being funded by $670,000 raised by the Ovarian Cancer Research Foundation, which was announced on Thursday as part of $2.4 million in grants.
“These funds have been raised by our community, so that’s people out there walking, running, baking, shaving their heads,” Georgie Herbert from the Ovarian Cancer Research Foundation told 9News.
.
Source: 9News with input from NIM
Follow us on Facebook: NIM Online, YouTube: NIM Online TV
Contact: Gmail: nimonlinemail@gmail.com